Current Report Filing (8-k)
August 12 2021 - 4:02PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
DC 20549
FORM 8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
Date
of report (Date of earliest event reported): August 12, 2021
TFF
PHARMACEUTICALS, INC.
(Exact
Name of Registrant as Specified in Its Charter)
Delaware
|
|
001-39102
|
|
82-4344737
|
(State
or Other Jurisdiction
of
Incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S.
Employer
Identification
Number)
|
2600
Via Fortuna, Suite 360
Austin,
Texas 78746
|
(Address
of principal executive offices)
|
(737)
802-1973
|
(Registrant’s
telephone number, including area code)
|
(Former
name or former address, if changed since last report)
|
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under
any of the following provisions.
|
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14d-2(b)
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities
registered pursuant to Section 12(b)of the Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
Common
stock: Par value $.001
|
|
TFFP
|
|
Nasdaq
Global Market
|
Item 2.02 Results
of Operations and Financial Condition.
On
August 12, 2021, TFF Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results for the
quarter ended June 30, 2021. A copy of the press release is attached as Exhibit 99.1 to this Current Report and is incorporated herein
by reference.
The
information in this Item 2.02, including the press release attached as Exhibit 99.1 hereto, is furnished pursuant to Item 2.02
but shall not be deemed “filed” for any purpose, including for the purposes of Section 18 of the Securities Exchange
Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it
be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether
made before or after the date hereof, regardless of any general incorporation language in such filing.
Item 9.01 Financial Statements and Exhibits
|
(d)
|
Exhibits
|
Method Filing
|
The following
exhibit is furnished with this report:
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
TFF
PHARMACEUTICALS, INC.
|
|
|
Dated:
August 12, 2021
|
/s/
Kirk Coleman
|
|
Kirk
Coleman,
|
|
Chief
Financial Officer
|
2
TFF Pharmaceuticals (NASDAQ:TFFP)
Historical Stock Chart
From Mar 2024 to Apr 2024
TFF Pharmaceuticals (NASDAQ:TFFP)
Historical Stock Chart
From Apr 2023 to Apr 2024